ARS Pharmaceuticals saw director Richard Lowenthal resign from the board and Chief Medical Officer Sarina Tanimoto leave the company, both effective July 15, 2026, with severance and prorated bonus payments agreed.
| IndividualRichard LowenthalSarina Tanimoto, M.D. | RoleMember of the Board of DirectorsChief Medical Officer | Type of ChangeResignedTerminated without cause / Ceased employment | Effective DateJuly 15, 2026July 15, 2026 | ReasonResignation was a condition to receive severance under his employment agreement and the Company's Change in Control and Severance Benefit PlanTermination without cause | Replacement InfoNot disclosedNot disclosed | Background DetailsReferenced employment agreement and Change in Control and Severance Benefit Plan per Proxy Statement dated April 29, 2026Served as Chief Medical Officer (no additional background disclosed) | Board/Committee Role ChangesNot disclosedNot disclosed | Severance / Additional PaymentSeverance per Proxy Statement plus one-time prorated 2026 bonus payment of $217,350, conditioned on release effectivenessSeverance per Proxy Statement plus one-time prorated 2026 bonus payment of $111,780, conditioned on release effectiveness |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.